Results 31 to 40 of about 37,898 (281)
Changes of calcium cycling in HFrEF and HFpEF
Mechanobiology in Medicine, 2023 Dysfunctions of calcium cycling occur in heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF). HFrEF and HFpEF showed Ca2+ leakage at diastole. The compensation of Na+/Ca2+ exchanger and the decrease of T-tubule density reduces cytoplasmic Ca2+ concentration in HFrEF and impairs systolic function.
Shou, Jian, Huo, Yunlong
openaire +2 more sources
The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal
Reviews in Cardiovascular Medicine, 2023 Heart failure with preserved ejection fraction (HFpEF) is frequently observed in elderly physically deconditioned subjects, mainly women with hypertension, obesity, glucose intolerance/diabetes, atrial fibrillation, anaemia, coronary artery disease ...
Gabriele Fragasso
doaj +1 more source
ESC Heart Failure, 2022 Iron deficiency (ID) is a common co‐morbidity in patients with heart failure (HF). The present meta‐analysis evaluates the effect of intravenous (IV) iron‐carbohydrate complex supplementation in patients with HF with reduced ejection fraction (HFrEF) and
A. Sindone, W. Doehner, J. Comín-Colet
semanticscholar +1 more source
Benefits of combination pharmacotherapy for HFrEF [PDF]
Nature Reviews Cardiology, 2020 In a new cross-trial analysis of patients with heart failure with reduced ejection fraction, researchers predict that a comprehensive strategy combining several pharmacological approaches reduces hospitalization and mortality compared with conventional therapy.
openaire +2 more sources
SGLT2 inhibitors: a new pillar of the heart failure regimen
Reviews in Cardiovascular Medicine, 2021 Initially intended as an adjunct treatment for type 2 diabetes mellitus (T2DM), SGLT2-inhibitors (SGLT2i) have transformed into an unexpected pillar of the heart failure (HF) regimen.
Travis DeSa +1 more
doaj +1 more source
Scientific Reports, 2022 The role of metformin (MET) in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus (DM) is not firmly established. We studied the impact of MET on metabolic profile, quality of life (QoL) and survival in these patients.
J. Beneš +12 more
semanticscholar +1 more source
Quadruple Therapy Is the New Standard of Care for HFrEF.
JACC: Heart Failure, 2020 T. Ahmad, N. Desai
semanticscholar +4 more sources
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
Journal of Clinical Medicine, 2022 Background: The new heart failure (HF) therapies of sodium-glucose cotransporter 2 inhibitors (SGLT2i), vericiguat, and omecamtiv mecarbil do not act primarily through the neuro-hormonal blockade, but have shown clinical benefits in patients with HF with
M. Pagnesi +8 more
semanticscholar +1 more source
Frontiers in Pharmacology, 2022 Background: Heart failure with reduced ejection fraction (HFrEF) is a complex, chronic disease and is among the top causes of morbidity and mortality. Angiotensin receptor-neprilysin inhibitor drugs represented by sacubitril/valsartan are the key drugs ...
Q. Xiang +8 more
semanticscholar +1 more source
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
European Heart Journal, Supplement, 2022 Large randomized controlled trials (RCTs) have led to major changes in the treatment of patients with heart failure and reduced left ventricular ejection fraction (HFrEF) and these advances are included in the recent European Society of Cardiology (ESC ...
D. Tomasoni +8 more
semanticscholar +1 more source